Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23835, expectations were $-0.28. Aclaris Therapeutics, Inc.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Deuterium Capital Management Osman Ozsan | 79,993 | $99,191 | 0.17% | |
2. | Endurant Capital Management Vishal Saluja And Pham Quang | 0 | $0 | 0% |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$1.25 | 6,000 | Director | 28,863 | 2024-03-04 | Filing | |
$1.23 | 8,500 | Director | 22,863 | 2024-03-01 | Filing | |
$7.90 | 9,490 | Officer | 15,461 | 2023-09-06 | Filing | |
$6.80 | 14,705 | Officer | 21,688 | 2023-08-28 | Filing | |
$7.86 | 6,300 | Officer, Director | 12,800 | 2023-03-17 | Filing |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$5.08 | 6,000 | Officer | 129,724 | 2023-10-23 | Filing | |
$7.32 | 6,000 | Officer | 135,724 | 2023-08-21 | Filing | |
$10.28 | 6,000 | Officer | 141,724 | 2023-06-20 | Filing | |
$12.63 | 30,240 | Director | 1,273,202 | 2023-03-03 | Filing | |
$12.37 | 29,000 | Director | 1,285,188 | 2023-03-02 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 5,905,872 | $6,201,167 | 0% | |
2. | 4,722,357 | $4,958,476 | 0% | |
3. | 3,500,000 | $3,675,000 | 0.35% | |
4. | 1,679,905 | $1,763,900 | 0% | |
5. | 1,463,461 | $1,536,634 | 0% |